

National Surveillance for *Candida auris*

Request for OMB approval of a New Information Collection

March 24, 2025

Supporting Statement B

Contact:

Rudith Vice

National Center for Emerging and Zoonotic Infectious Diseases

Centers for Disease Control and Prevention

1600 Clifton Road, NE

Atlanta, Georgia 30333

Phone: (404) 718-7292

Email: nhr9@cdc.gov

Table of Contents

1. Respondent Universe and Sampling Methods.....	2
2. Procedures for the Collection of Information.....	2
3. Methods to maximize Response Rates and Deal with No Response.....	2
4. Tests of Procedures or Methods to be Undertaken.....	2
5. Individuals Consulted on Statistical Aspects and Individuals Collecting and/or Analyzing Data.....	2

The collection does not involve statistical methods, and the purpose of the collection is not to make statistical generalizations beyond the particular respondents.

1. Respondent Universe and Sampling Methods

The data will be analyzed in coordination with the states/jurisdictions that submit data.

2. Procedures for the Collection of Information

C. auris is a nationally notifiable condition and reportable in many jurisdictions. Cases identified through positive clinical specimens or colonization screening (with testing performed by public health, clinical, or commercial labs) based on the CSTE case definition are reported by laboratories or healthcare facilities to the local or state health department. Information collected for each case from reporting laboratories or healthcare facilities through case investigations by local/state health departments will be submitted to CDC using REDCap. The information submitted will include basic information about patient demographics (e.g., age, sex, location of residence, case type), specimen information (e.g., specimen type, date of collection), location and healthcare facility of specimen collection, and mortality.

3. Methods to maximize Response Rates and Deal with No Response

As we have close contact with jurisdictions and since *C. auris* is nationally notifiable, with several jurisdictions deeming *C. auris* as a reportable disease, we believe that there is strong interest in capturing all cases that are laboratory confirmed.

4. Tests of Procedures or Methods to be undertaken

No pre-tests are planned.

5. Individuals Consulted on Statistical Aspects and Individuals Collecting and/or Analyzing Data

Anna Baker/CDC/DFWED/NCEZID; telephone number: 404.718.3620; email: ucd4@cdc.gov

Meghan Lyman/CDC/DFWED/NCEZID; telephone number: 404.639.4241; email: yeo4@cdc.gov

Sophie Allen/CDC/DFWED/NCEZID; hte6@cdc.gov